The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
Screening of disease-linked cell types might bolster drug discovery efforts in schizophrenia, according to a proof-of-concept study.
The funding is being provided by Genome Canada, as well as various Canadian provinces, businesses, and research institutes.
A CIO panel discussed why genomics IT is prepared for new security challenges and why organizations need to step up staff training and retention strategies.
The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.
The project team is driving the development of practice guidelines because sample handling and quality are often not up to the mark.
Thermo Fisher Scientific, Illumina, Eli Lilly, Celgene, and Roche/Genentech have committed their expertise and funding to build a lung cancer registry.
In the study, called TAPUR, ASCO will give cancer patients who are out of treatment options off-label drugs based on their genomic data and record their outcomes in a registry.
Lilly decided to stop developing the drug in 2012, but Denovo thinks it can identify a subset of genetically defined patients that can benefit from the drug.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.